NCT03740373 - A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

October 11, 2018

Study Completion Date

October 11, 2018

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold

Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.

DRUG

BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold

Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.

Trial Locations (1)

Research Site, Pentrebach